nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-179-7-69-77nogr-1398Research ArticleКЛИНИЧЕСКАЯ ГАСТРОЭНТЕРОЛОГИЯCLINICAL GASTROENTEROLOGYМикробиоценоз кишечника у больных с рецидивирующей инфекцией Clostridium difficile, язвенным колитом и синдромом раздраженной кишки после трансплантации фекальной микрофлорыIntestinal microbiocenosis in patients with recurrent Clostridium difficile infection, ulcerative colitis and irritable bowel syndrome after transplantation of fecal microflorahttps://orcid.org/0000-0003-3606-4068ШрайнерЕ. В.ShrainerE. V.

Шрайнер Евгения Владимировна - кандидат медицинских наук, старший преподаватель, институт медицины и психологии В. Зельмана.630090, Новосибирск, ул. Пирогова, 1.

Evgenia V. Shrainer - MD, PhD, Senior Lecturer, Institute of Medicine and Psychology V. Zelman.630090, Novosibirsk, st. Pirogova, 1.

sch704@icloud.comhttps://orcid.org/0000-0001-7308-7280ХавкинА. И.KhavkinA. I.

Хавкин Анатолий Ильич - доктор медицинских наук, профессор, руководитель отдела гастроэнтерологии Научно-исследовательского клинического института педиатрии им. академика Ю.Е. Вельтищева.Москва.

Anatoly I. Khavkin - MD, PhD, DSc, professor, head of the department of gastroenterology, Academician Yu.E. Veltishchev.2 Taldomskaya str., Moscow, 125412.

ВласовВ. В.VlasovV. V.

Власов Валентин Викторович - академик РАН, доктор химических наук, профессор, научный руководитель Института; член Президиума СО РАН, бюро Отделения биологических наук РАН, объединенного ученого совета по биологическим.630090, Новосибирск, проспект Лаврентьева, 8.

Valentin V. Vlasov - academician of the Russian Academy of Sciences, doctor of chemical sciences, professor, scientific adviser of the Institute; Member of the Presidium of the SB RAS, Bureau of the Department of Biological Sciences of the Russian Academy of Sciences, Joint Scientific Council for Biological Sciences of the SB RAS.630090, Novosibirsk, Lavrentiev Avenue, 8.

Новосибирский государственный университетРоссияNovosibirsk State UniversityRussian FederationРоссийский национальный исследовательский медицинский университет им. Н.И. ПироговаРоссияResearch and Clinical Institute of Pediatrics at the N.I. Pirogov Russian National Research Medical UniversityRussian FederationИнститут химической биологии и фундаментальной медицины СО РАНРоссияScientific adviser of the Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch of the Russian Academy of SciencesRussian Federation202027092020076977Copyright © Шрайнер Е.В., Хавкин А.И., Власов В.В., 20202020Шрайнер Е.В., Хавкин А.И., Власов В.В.Shrainer E.V., Khavkin A.I., Vlasov V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/1398

Выявленные значительные изменения микробиома кишечника у больных с воспалительными заболеваниями кишечника (ВЗК), служат причиной для терапевтических вмешательств с целью его коррекции. Трансплантация фекальной микробиоты (ТФМ) является эффективным методом лечения рецидивирующей или рефрактерной инфекции Clostridium difficile, в том числе, и у пациентов с воспалительными заболеваниями кишечника, получающих иммуносупрессивную и антицитокиновую терапию.Приведены результаты изучения эффективности ТФМ с помощью отфильтрованной водной суспензии фекалий доноров при коррекции нарушений микробиоценоза кишечника у пациентов с рецидивирующей клостридиальной инфекцией (РКИ), язвенным колитом (ЯК) и синдромом раздраженного кишечника (СРК). Через 2 недели после введения надосадочной жидкости суспензии микроорганизмов фекальной микрофлоры у пациентов оценивали динамику общего содержания микроорганизмов и отдельных представителей кишечной микрофлоры. Установлено, что надосадочная жидкость водной суспензии фекалий доноров, содержащая микробные экзометаболиты и другие биологически активные соединения, оказывает в короткие сроки наиболее выраженное влияние на восстановление нормальной кишечной микрофлоры только у пациентов с клостридиальной инфекцией.

Identified significant changes in the intestinal microbiome in patients with inflammatory bowel disease (IBD), serve as the reason for therapeutic interventions in order to correct it. Faecal microbiota transplantation (TFM) is an effective treatment for recurrent or refractory Clostridium difficile infections, including in patients with inflammatory bowel diseases receiving immunosuppressive and anticytokine therapy.The results of studying the effectiveness of TFM using a filtered aqueous suspension of donors feces in the correction of intestinal microbiocenosis in patients with recurrent Clostridial infection (RCT), ulcerative colitis (UC) and irritable bowel syndrome (IBS) are presented. 2 weeks after the introduction of the supernatant, a suspension of fecal microorganism microorganisms in patients evaluated the dynamics of the total content of microorganisms and individual representatives of the intestinal microflora. It was found that the supernatant of an aqueous suspension of donor feces containing microbial exometabolites and other biologically active compounds in the short term has the most pronounced effect on the restoration of normal intestinal microflora only in patients with clostridial infection.

Трансплантация фекальной микробиотыязвенный колитсиндром раздражённого кишечникаинфекция Clostridium difficileFaecal microbiota transplantationulcerative colitisirritable bowel syndromeClostridium difficile infectionReferencesКорниенко Е.А., Хавкин А. И., Федулова Е. Н., Волынец Г. В., Габрусская Т. В., Скворцова Т. А., Никитин А. В., Сорвачева Т. Н., Цимбалова Е. Г., Щербакова О. В. Болезнь Крона у детей: диагностика и лечение. В сборнике: Избранные труды Общества детских гастроэнтерологов, гепатологов и нутрициологов «Детская гастроэнтерология 2019» Избранные труды Общества детских гастроэнтерологов, гепатологов и нутрициологов. Под общей редакцией А. И. Хавкина, В. П. Новиковой, Г. В. Волынец. Москва-Санкт-Петербург, 2019. С. 77-131.Kornienko E. A., Khavkin A. I., Fedulova E. N., et al. Crohn's disease in children: diagnosis and treatment. In the collection: Selected works of the Society of Pediatric Gastroenterologists, Hepatologists and Nutritionists “Children's Gastroenterology 2019” Selected works of the Society of Pediatric Gastroenterologists, Hepatologists and Nutritionists. Moscow-St. Petersburg, 2019. pp. 77-131.Шрайнер Е.В., Морозов В. В., Хавкин А. И., Власов В. В., Куликов В. Г., Кольцова С. Т. Опыт проведения трансплантации фекальной микробиоты у пациентки с клостридиальной инфекцией. Экспериментальная и клиническая гастроэнтерология. 2018. № 12 (160). С. 80-83 DOI: 10.31146/1682-8658-ecg-160-12-80-83Shrainer E. V., Morozov V. V., Khavkin A. I., et al. Experience with transplantation of fecal microbiota in a patient with clostridial infection. Experimental and clinical gastroenterology. 2018. No 12 (160), pp. 80-83. DOI: 10.31146/1682-8658-ecg-160-12-80-83Хавкин А.И., Шрайнер Е. В., Денисов М. Ю., Деровс А. А., Горелова Ю. С. Трансплантация фекальной микрофлоры при воспалительных заболеваниях кишечника у детей: опыт и перспективы. Вопросы практической педиатрии. 2018. Т. 13. № 3. С. 20-28. DOI: 10.20953/1817-7646-2018-3-20-28.Khavkin A. I., Shrainer E. V., Denisov M. Yu., Derovs A. A., Gorelova Yu. S. Transplantation of fecal microflora in inflammatory bowel diseases in children: experience and prospects. Questions of practical pediatrics. 2018. Vol. 13, No. 3, pp. 20-28. DOI: 10.20953/1817-76462018-3-20-28Хавкин А.И., Алёшкин А. В., Зейгарник М. В. Перспективы фаготерапии при болезнях органов пищеварения у детей. Вопросы практической педиатрии. 2018. Т. 13. № 4. С. 82-90. DOI: 10.20953/18177646-2018-4-82-90.Khavkin A. I., Alyoshkin A. V., Zeigarnik M. V. Prospects for phage therapy for diseases of the digestive system in children. Questions of practical pediatrics. 2018, Vol. 13, No. 4, pp. 82-90. DOI: 10.20953/1817-7646-20184-82-90Корниенко Е.А., Хавкин А. И., Федулова Е. Н., Волынец Г. В., Габрусская Т. В., Скворцова Т. А., Никитин А. В., Сорвачева Т. Н., Цимбалова Е. Г., Щербакова О. В. Проект рекомендаций Российского общества детских гастроэнтерологов, гепатологов и нутрициологов по диагностике и лечению болезни Крона у детей. Экспериментальная и клиническая гастроэнтерология. 2019. № 11 (171). С. 100-134. DOI: 10.31146/1682-8658-ecg-171-11-100-134Kornienko E. A., Khavkin A. I., Fedulova E. N., et al. Draft recommendations of the Russian Society of Pediatric Gastroenterologists, Hepatologists and Nutritionists on the Diagnosis and Treatment of Crohn's Disease in Children. Experimental and clinical gastroenterology. 2019. No 11 (171), pp. 100-134. DOI: 10.31146/1682-8658-ecg-171-11-100-134.Khanna S, Raffals LE. The Microbiome in Crohn's Disease: Role in Pathogenesis and Role of Microbiome Replacement Therapies. Gastroenterol Clin North Am. 2017 Sep;46(3):481-492. doi: 10.1016/j.gtc.2017.05.004. Epub 2017 Jul 19.Khanna S, Raffals LE. The Microbiome in Crohn's Disease: Role in Pathogenesis and Role of Microbiome Replacement Therapies. Gastroenterol Clin North Am. 2017 Sep;46(3):481-492. doi: 10.1016/j.gtc.2017.05.004. Epub 2017 Jul 19.van Nood E, Dijkgraaf MG, Keller JJ. Duodenal infusion of feces for recurrent Clostridium difficile. N Engl J Med 2013;368(22):2145. Kassam Z, Lee CH, Yuan Y, et al. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108:500-508.van Nood E, Dijkgraaf MG, Keller JJ. Duodenal infusion of feces for recurrent Clostridium difficile. N Engl J Med 2013;368(22):2145. Kassam Z, Lee CH, Yuan Y, et al. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108:500-508.Inflammatory Bowel Disease Collaborators Lancet Gastroenterol Hepatol 2020; 5: 17-30, doi.org/10.1016/S2468-1253(19)30333-4Inflammatory Bowel Disease Collaborators Lancet Gastroenterol Hepatol 2020; 5: 17-30, doi.org/10.1016/S2468-1253(19)30333-4Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106:661-673.Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106:661-673.Chibbar R, Dieleman LA. Probiotics in the management of ulcerative colitis. J Clin Gastroenterol. 2015;49(suppl 1): S50-S55Chibbar R, Dieleman LA. Probiotics in the management of ulcerative colitis. J Clin Gastroenterol. 2015;49(suppl 1): S50-S55Moayyedi P. Fecal transplantation: any real hope for inflammatory bowel disease? Curr Opin Gastroenterol. 2016;32:282-286Moayyedi P. Fecal transplantation: any real hope for inflammatory bowel disease? Curr Opin Gastroenterol. 2016;32:282-286Chen SJ, Liu XW, Liu JP, Yang XY, Lu FG. Ulcerative colitis as a polymicrobial infection characterized by sustained broken mucus barrier. World J Gastroenterol. 2014 Jul 28;20(28):9468-9475. doi: 10.3748/wjg.v20.i28.9468Chen SJ, Liu XW, Liu JP, Yang XY, Lu FG. Ulcerative colitis as a polymicrobial infection characterized by sustained broken mucus barrier. World J Gastroenterol. 2014 Jul 28;20(28):9468-9475. doi: 10.3748/wjg.v20.i28.9468Sartor RB, Wu GD. Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of Inflammatory Bowel Diseases and Therapeutic Approaches. Gastroenterology. 2017 Feb;152(2):327-339.e4. doi: 10.1053/j.gastro.2016.10.012.Sartor RB, Wu GD. Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of Inflammatory Bowel Diseases and Therapeutic Approaches. Gastroenterology. 2017 Feb;152(2):327-339.e4. doi: 10.1053/j.gastro.2016.10.012.Waldschmitt N, Metwaly A, Fischer S, Haller D. Microbial Signatures as a Predictive Tool in IBD-Pearls and Pitfalls. Inflamm Bowel Dis. 2018 May 18;24(6):1123-1132. doi: 10.1093/ibd/izy059Waldschmitt N, Metwaly A, Fischer S, Haller D. Microbial Signatures as a Predictive Tool in IBD-Pearls and Pitfalls. Inflamm Bowel Dis. 2018 May 18;24(6):1123-1132. doi: 10.1093/ibd/izy059Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014 May;14(5):329-342. doi: 10.1038/nri3661.Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014 May;14(5):329-342. doi: 10.1038/nri3661.Miner-Williams WM, Moughan PJ. Intestinal barrier dysfunction: implications for chronic inflammatory conditions of the bowel. Nutr Res Rev. 2016 Jun;29(1):40-59. doi: 10.1017/S0954422416000019.Miner-Williams WM, Moughan PJ. Intestinal barrier dysfunction: implications for chronic inflammatory conditions of the bowel. Nutr Res Rev. 2016 Jun;29(1):40-59. doi: 10.1017/S0954422416000019.Vigsn&sLK, Brynskov J, Steenholdt C, Wilcks A, Licht TR. Gram-negative bacteria account for main differences between faecal microbiota from patients with ulcerative colitis and healthy controls. Benef Microbes. 2012 Dec 1;3(4):287-297. doi: 10.3920/BM2012.0018.Vigsn&sLK, Brynskov J, Steenholdt C, Wilcks A, Licht TR. Gram-negative bacteria account for main differences between faecal microbiota from patients with ulcerative colitis and healthy controls. Benef Microbes. 2012 Dec 1;3(4):287-297. doi: 10.3920/BM2012.0018.Wrzosek L, Miquel S, Noordine ML, Bouet S, et al. Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent. BMC Biol. 2013 May 21;11:61. doi: 10.1186/1741-7007-11-61Wrzosek L, Miquel S, Noordine ML, Bouet S, et al. Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent. BMC Biol. 2013 May 21;11:61. doi: 10.1186/1741-7007-11-61Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012 Sep 13;489(7415):220-230. doi: 10.1038/nature11550.Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012 Sep 13;489(7415):220-230. doi: 10.1038/nature11550.Ситкин С.И., Ткаченко Е. И., Вахитов Т. Я. Филометаболическое ядро микробиоты кишечника // Альманах клинической медицины. - 2015. - № 40. -С. 12-34. - doi: 10.18786/2072-0505-2015-40-12-34Sitkin S. I., Tkachenko E. I., Vakhitov T. Ya. Phylo-metabolic core of intestinal microbiota. Clinical medicine almanac. 2015, No. 40, pp. 12-34. doi: 10.18786/2072-0505-2015-40-12-34Salonen A, Salojarvi J, Lahti L, de Vos WM. The adult intestinal core microbiota is determined by analysis depth and health status. Clin Microbiol Infect. 2012 Jul;18 Suppl 4:16-20. doi: 10.1111/j.1469-0691.2012.03855.xSalonen A, Salojarvi J, Lahti L, de Vos WM. The adult intestinal core microbiota is determined by analysis depth and health status. Clin Microbiol Infect. 2012 Jul;18 Suppl 4:16-20. doi: 10.1111/j.1469-0691.2012.03855.xMorgan XC, Tickle TL, Sokol H, et al. Huttenhower C. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012 Apr 16;13(9): R79. doi: 10.1186/gb-2012-13-9-r79Morgan XC, Tickle TL, Sokol H, et al. Huttenhower C. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012 Apr 16;13(9): R79. doi: 10.1186/gb-2012-13-9-r79Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014 Aug;63(8):1275-1283. doi: 10.1136/gutjnl-2013-304833.Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014 Aug;63(8):1275-1283. doi: 10.1136/gutjnl-2013-304833.Takahashi K, Nishida A, Fujimoto T, Fujii M, Shioya M, Imaeda H, Inatomi O, Bamba S, Sugimoto M, Andoh A. Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease. Digestion. 2016;93(1):59-65. doi: 10.1159/000441768.Takahashi K, Nishida A, Fujimoto T, Fujii M, Shioya M, Imaeda H, Inatomi O, Bamba S, Sugimoto M, Andoh A. Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease. Digestion. 2016;93(1):59-65. doi: 10.1159/000441768.Duboc H, Rajca S, Rainteau D, et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2013 Apr;62(4):531-539. doi: 10.1136/gutjnl-2012-302578.Duboc H, Rajca S, Rainteau D, et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2013 Apr;62(4):531-539. doi: 10.1136/gutjnl-2012-302578.Ситкин С.И., Вахитов Т. Я., Ткаченко Е. И., Орешко Л. С., Жигалова Т. Н., Радченко В. Г., Селиверстов П. В., Авалуева Е. Б., Суворова М. А., Комличенко Э. В. Микробиота кишечника при язвенном колите и целиакии // Экспериментальная и клиническая гастроэнтерология. - 2017. - № 1 (137). - С. 8-30.Sitkin S. I., Vakhitov T. Ya., Tkachenko E. I., et al. Intestinal microbiota in colitis and celiac disease. Experimental and clinical gastroenterology. - 2017, No. 1 (137), pp. 8-30.Rehman A, Rausch P, Wang J, Skieceviciene J, et al. Geographical patterns of the standing and active human gut microbiome in health and IBD. Gut. 2016 Feb;65(2):238-248. doi: 10.1136/gutjnl-2014-308341Rehman A, Rausch P, Wang J, Skieceviciene J, et al. Geographical patterns of the standing and active human gut microbiome in health and IBD. Gut. 2016 Feb;65(2):238-248. doi: 10.1136/gutjnl-2014-308341Kang S, Denman SE, Morrison M, Yu Z, Dore J, Leclerc M, McSweeney CS. Dysbiosis of fecal microbiota in Crohn's disease patients as revealed by a custom phylogenetic microarray. Inflamm Bowel Dis. 2010 Dec;16(12):2034-2042. doi: 10.1002/ibd.21319.Kang S, Denman SE, Morrison M, Yu Z, Dore J, Leclerc M, McSweeney CS. Dysbiosis of fecal microbiota in Crohn's disease patients as revealed by a custom phylogenetic microarray. Inflamm Bowel Dis. 2010 Dec;16(12):2034-2042. doi: 10.1002/ibd.21319.Vigsnaes LK, van den Abbeele P, Sulek K, et al. Microbiotas from UC patients display altered metabolism and reduced ability of LAB to colonize mucus. Sci Rep. 2013;3:1110. doi: 10.1038/srep01110.Vigsnaes LK, van den Abbeele P, Sulek K, et al. Microbiotas from UC patients display altered metabolism and reduced ability of LAB to colonize mucus. Sci Rep. 2013;3:1110. doi: 10.1038/srep01110.Fite A, Macfarlane S, Furrie E, Bahrami B, Cummings JH, Steinke DT, Macfarlane GT. Longitudinal analyses of gut mucosal microbiotas in ulcerative colitis in relation to patient age and disease severity and duration. J Clin Microbiol. 2013 Mar;51(3):849-856. doi: 10.1128/JCM.02574-12.Fite A, Macfarlane S, Furrie E, Bahrami B, Cummings JH, Steinke DT, Macfarlane GT. Longitudinal analyses of gut mucosal microbiotas in ulcerative colitis in relation to patient age and disease severity and duration. J Clin Microbiol. 2013 Mar;51(3):849-856. doi: 10.1128/JCM.02574-12.Fyderek K, Strus M, Kowalska-Duplaga K, et al. Mucosal bacterial microflora and mucus layer thickness in adolescents with inflammatory bowel disease. World J Gastroenterol. 2009 Nov 14;15(42):5287-5294. doi: 10.3748/wjg.15.5287.Fyderek K, Strus M, Kowalska-Duplaga K, et al. Mucosal bacterial microflora and mucus layer thickness in adolescents with inflammatory bowel disease. World J Gastroenterol. 2009 Nov 14;15(42):5287-5294. doi: 10.3748/wjg.15.5287.Kabeerdoss J, Jayakanthan P, Pugazhendhi S, Ramakrishna BS. Alterations of mucosal microbiota in the colon of patients with inflammatory bowel disease revealed by real time polymerase chain reaction amplification of 16S ribosomal ribonucleic acid. Indian J Med Res. 2015 Jul;142(1):23-32. doi: 10.4103/0971-5916.162091.Kabeerdoss J, Jayakanthan P, Pugazhendhi S, Ramakrishna BS. Alterations of mucosal microbiota in the colon of patients with inflammatory bowel disease revealed by real time polymerase chain reaction amplification of 16S ribosomal ribonucleic acid. Indian J Med Res. 2015 Jul;142(1):23-32. doi: 10.4103/0971-5916.162091.Th orkildsen LT, Nwosu FC, Avershina E, et al. Dominant fecal microbiota in newly diagnosed untreated inflammatory bowel disease patients. Gastroenterol Res Pract. 2013;2013:636785. doi: 10.1155/2013/636785Thorkildsen LT, Nwosu FC, Avershina E, et al. Dominant fecal microbiota in newly diagnosed untreated inflammatory bowel disease patients. Gastroenterol Res Pract. 2013;2013:636785. doi: 10.1155/2013/636785Sokol H, Seksik P, Furet JP, Firmesse O, et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis. 2009 Aug;15(8):1183-1189. doi: 10.1002/ibd.20903.Sokol H, Seksik P, Furet JP, Firmesse O, et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis. 2009 Aug;15(8):1183-1189. doi: 10.1002/ibd.20903.Paramsothy S, Paramsothy R, Rubin DT, Kamm MA, Kaakoush NO, Mitchell HM, Castano-RodHguez N. Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. J Crohns Colitis. 2017 Oct 1;11(10):1180-1199. doi: 10.1093/ecco-jcc/jjx063.Paramsothy S, Paramsothy R, Rubin DT, Kamm MA, Kaakoush NO, Mitchell HM, Castano-RodHguez N. Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. J Crohns Colitis. 2017 Oct 1;11(10):1180-1199. doi: 10.1093/ecco-jcc/jjx063.Narula N., Kassam Z., Yuan Y. et al. Systematic review and meta-analysis: fecal microbiota transplantation for treatment of active ulcerative colitis. Inflamm Bowel Dis 2017;0:1-8Narula N., Kassam Z., Yuan Y. et al. Systematic review and meta-analysis: fecal microbiota transplantation for treatment of active ulcerative colitis. Inflamm Bowel Dis 2017;0:1-8Nagao-Kitamoto H, Kitamoto S, Kuff a P, Kamada N. Pathogenic role of the gut microbiota in gastrointestinal diseases. Intest Res. 2016 Apr;14(2):127-138. doi: 10.5217/ir.2016.14.2.127.Nagao-Kitamoto H, Kitamoto S, Kuff a P, Kamada N. Pathogenic role of the gut microbiota in gastrointestinal diseases. Intest Res. 2016 Apr;14(2):127-138. doi: 10.5217/ir.2016.14.2.127.Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infec Dis. - 2011. - Vol. 53 - P. 994-1002Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infec Dis. - 2011. - Vol. 53 - P. 994-1002Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149:102-109. e6.Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149:102-109. e6.Vermeire S, Joossens M, Verbeke K, et al. Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. J Crohns Colitis. 2016;10:387-394.Vermeire S, Joossens M, Verbeke K, et al. Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. J Crohns Colitis. 2016;10:387-394.Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149:110-108. e4Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149:110-108. e4Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389:1218-1228.Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389:1218-1228.

The authors declare that there are no conflicts of interest present.